Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Gynecologic Oncology

RSS  

Articles

  • Research eyes DMPA, cancer risks/benefits

    Family planning clinicians are familiar with the injectable contraceptive depot medroxyprogesterone acetate (DMPA) as an effective form of reversible birth control, following only the contraceptive implant and intrauterine device (IUD) in contraceptive efficacy.
  • STI Quarterly: View webinar on drug-resistant gonorrhea

    The Centers for Disease Control and Prevention (CDC) has a free webinar of its recent Public Health Grand Rounds, "The Growing Threat of Multidrug-Resistant Gonorrhea, available on its web site.
  • STI Quarterly: Improve rates now to finish HPV vaccination

    Review the records of the girls who have received at least one injection in the three-series vaccination series for human papillomavirus (HPV). How many have completed the series? If new research is any indication, the proportion of those receiving all three shots is low.
  • Long-acting reversible methods said superior in effectiveness

    Family planners now have proof positive that the intrauterine device (IUD) and the contraceptive implant, two long-acting reversible contraceptives (LARC methods), are superior in their effectiveness, compared to the effectiveness of the contraceptive pill, patch, or ring.
  • Clinical Briefs in Primary Care Supplement

  • Diabetes as a Risk Factor for Hematologic Malignancy

    In a meta-analysis of current observational (both case-control and prospective cohort) studies evaluating the potential association between type 2 diabetes mellitus and the incidence of hematological malignancy, an increased risk for non-Hodgkin lymphoma and leukemia was demonstrated as well as a trend toward an increased risk for myeloma. Confounding factors such as age, obesity, smoking, and alcohol (risks for both diabetes and malignancy) could not be completely accounted for in such an analysis.
  • Pharmacology Watch

    Azithromycin and cardiac risk; warfarin and heart failure; aspirin and VTE; effectiveness of long-acting contraceptives; and FDA actions.
  • Controlling Pegfilgrastim Bone Pain

    This randomized, placebo-controlled, Phase 3 clinical trial showed that the majority of patients treated with pegfilgrastim experience bone pain, and that taking 500 mg of naproxen twice a day decreases its incidence and severity.
  • Monoclonal Gammopathy of Undetermined Significance

    A 64-year-old commercial airline pilot was seen by his primary physician because of a bothersome, non-productive cough. He has a history of asthma but requires no medications other than occasional albuterol inhalation. Physical examination was unremarkable, as were the complete blood count and chest x-ray.
  • Cancer Prevention by Aspirin: A New Evaluation of Existing Data

    By a systematic review of observational (case-control and cohort) studies, data regarding aspirin use and cancer risk were compared to data obtained from randomized clinical trials. In general, there was very good correlation regarding reduced risk for several types of cancer and the development of metastatic disease. The analysis provides confidence that observational studies can be of value in addressing the many outstanding questions regarding aspirin and cancer prevention.